Focal Onset Seizure
Neurology
5
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
2
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
3
Early DiscoveryClinical DevelopmentMarket
On Market (2)
Approved therapies currently available
U
CENOBAMATEApproved
cenobamate
Unknown CompanyCompetitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2024
2025
2026
2027
SK Life ScienceCenobamate
Precision BioSciences30mg PRAX-628
Clinical Trials (2)
Total enrollment: 50 patients across 2 trials
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
Start: Oct 2024Est. completion: Jul 2027
Phase 4Active Not Recruiting
An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures
Start: Jan 2025Est. completion: Jul 202550 patients
Phase 2Recruiting
Related Jobs in Neurology
Director, Distribution & Services
Xenon Pharmaceuticals
Remote
10h ago
Senior Medical Science Liaison (NYC Tri-State)
Xenon Pharmaceuticals
Remote
10h ago
$208K - $234K/yr
Director of Medical Affairs
CoMind
Miami, FL
10h ago
Director of Finance
CoMind
London, UK
10h ago
Electronics Engineering Manager
CoMind
London, UK
10h ago
Director of Information Technology
Zavation Medical Products
10h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 50 patients
3 companies competing in this space